CEEPC/IPM/CMSC - Abstrakt prezentace

(CEEPC/IPM/CMSC 2022 - ThP-19)
Multi-omics approach to a comprehensive analysis of blood plasma for clinical diagnostics of hepatocellular carcinoma

Tatiana Smirnova 1 *, Kateřina Králová 2, Markéta Fousková 2, Ondřej Vrtělka 2, Lenka Michálková 2,3, Štěpánka Kučková 4, Vladimír Setnička 2

  1. Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Prague
  2. Department of Analytical Chemistry, University of Chemistry and Technology, Prague
  3. Department of Analytical Chemistry, Institute of Chemical Processes Fundamentals of the Czech Academy of Sciences, Prague
  4. Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague


In 2020, hepatocellular carcinoma (HCC) takes fifth place worldwide in cancer mortality (more than 8% of the deaths). The early diagnosis of HCC would dramatically increase the chance for survival. Nowadays, most patients are diagnosed in advanced stages of the disease when no effective clinical treatment is possible and five-year survival rate across all stages reaches only 20%. HCC is often associated with at-risk group of patients with chronic liver disease. However, the current screening methods, based mainly on ultrasound examination, are not effective enough for early-stage detection (sensitivity being only around 50%).
Pathological processes associated with the presence of the disease in a human body may cause changes in the content and structure of various types of biomolecules. These changes may be observed in biofluids, e.g. blood plasma, which is collected using routine and almost non-invasive procedure and the collection is cost-effective. Blood plasma is in direct contact with tissues and contains a wide spectrum of signalling molecules, which may be affected by the current health condition.
This project aims to combine information from several analytical methods (FTIR, Raman spectroscopy, NMR, MALDI-TOF-MS, LC-ESI-Q-TOF) to create a panel of specific blood plasma-based biomarkers with the ability to differentiate HCC from controls (cirrhotic patients and healthy persons). To obtain different fractions of the sample for mass spectrometric techniques, we employed a combination of physical (plasma filtration with different cut-offs) and chemical separation methods (lipid separation using butanol/diisopropil ether (40/60)). MALDI-TOF-MS was used for analyses of the low- and high-molecular-weight blood plasma fractions as well as extracted plasma proteins.

* Korespondující autor: smirnovt@vscht.cz


  1. Sung H. et al., CA Cancer J. Clin. 71(3), 209-249 (2021).
  2. Tzartzeva K. et al., Gastroenterology 154(6), 1706-1718 (2018).
  3. Zhang J. et al., PLOS ONE 15(2), e0228857 (2020).


This work was supported from the OP RDE registration no.: CZ.02.2.69/0.0/0.0/19_073/0016928, funded by the ESF.

Partneři společnosti

LabRules LCMS LabRules GCMS


Bruker HPST Merck Pragolab Amedis EastPort Shimadzu Waters